Shares of Inflarx NV (NASDAQ:IFRX) have received a consensus recommendation of “Hold” from the eleven brokerages that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation and nine have assigned a hold recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $6.20.
Several research analysts recently commented on the stock. Zacks Investment Research lowered shares of Inflarx from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. Robert W. Baird lowered shares of Inflarx from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $58.00 to $6.00 in a research note on Wednesday.
A number of institutional investors have recently modified their holdings of IFRX. FMR LLC acquired a new position in Inflarx during the 1st quarter valued at approximately $9,609,000. Redmile Group LLC increased its stake in Inflarx by 7.2% during the 1st quarter. Redmile Group LLC now owns 2,182,638 shares of the company’s stock valued at $82,482,000 after purchasing an additional 147,238 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in Inflarx during the 1st quarter valued at approximately $4,481,000. RA Capital Management LLC increased its stake in Inflarx by 6.0% during the 4th quarter. RA Capital Management LLC now owns 2,085,089 shares of the company’s stock valued at $75,835,000 after purchasing an additional 117,241 shares in the last quarter. Finally, Vanguard Group Inc increased its stake in Inflarx by 137.4% during the 3rd quarter. Vanguard Group Inc now owns 162,460 shares of the company’s stock valued at $5,576,000 after purchasing an additional 94,020 shares in the last quarter. Institutional investors and hedge funds own 55.89% of the company’s stock.
Inflarx (NASDAQ:IFRX) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.02). On average, sell-side analysts expect that Inflarx will post -2.1 earnings per share for the current year.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.